 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Alzheimer’s in the NewsThe 11th International Conference on Alzheimer’s Disease (ICAD), sponsored by the Alzheimer’s Association, was held this past July in Chicago, IL. The meeting consisted of over 5,000 participants, which was the largest number of Alzheimer’s disease (AD) researchers to have ever gathered for such a meeting. Researchers and healthcare providers presented cutting edge research results and current educational initiatives related to AD. Several clinical researchers from the Boston University Alzheimer’s Disease Center (BU ADC) attended this meeting, with many faculty members and affiliates presenting their research findings. Dr. Robert Green, BU ADC Clinical Core Director, gave a talk entitled, “Safety and efficacy of tarenflurbil in subjects with mild AD: Results from an 18-month multi-center Phase III trial.” Tarenflurbil (Flurizan) had shown promising results in prior trials and is known to lower levels of amyloid beta peptide, which is thought to be a contributing cause in AD. The most recent Phase III trial revealed that patients taking tarenflurbil did not significantly differ from patients who took a placebo, or sugar pill, in cognition, performance of everyday activities, or a rating of dementia severity. The next ICAD meeting is scheduled to be held in Vienna, Austria on July 11-16, 2009. More information about this conference can be found online at www.alz.org/icad/. |
|
 |
 |
 |
 |
 |
|